Who’s Going to ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

231 organizations and 272 people on the program at the American College of Toxicology (ACT) 2026 Annual Meeting, a ~1,400-person, mostly industry meeting of pharma, biotech and CRO toxicologists. As of Oct 8, 2026.

Format
Topic
Top represented
Showing 1–3 of 231 organizations
OrganizationACT 2026 Attendance
Government agencies and regulators
US agency regulating drugs and biologics; its reviewers and researchers present on NAMs, immunosafety, genetic toxicology and carcinogenicity.
Talk
Sun Nov 15
8:30am–9:00am
Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4)
Ideal Interaction During Drug Development: FDA Regulator's Perspective (CE4-3)
Regulatory
Session
Sun Nov 15
1:00pm–4:30pm
Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5)
New approach methods · with Labcorp
  1. 1:00pmIntroduction (CE5-1)U.S. Food and Drug Administration
  2. 1:05pmFDA's 2025 Roadmap to Reduce Animal Testing: Leveraging NAMs to Address Preclinical Safety (CE5-2)U.S. Food and Drug Administration
  3. 1:30pmNew Approach Methodologies (NAMs): Role of Nonclinical Scientists (CE5-3)Gilead Sciences
  4. 2:00pmComplex Human-Derived Models as New Approach Methodologies (NAMs) for Drug Discovery and Development (CE5-4)Sanofi
  5. 3:00pmNew Approach Methodologies in Practice: Creating Virtual Control Groups for Nonclinical Studies (CE5-5)Labcorp
  6. 3:30pmNAMs Adoption in a Global Drug Development Laboratory (CE5-6)Labcorp
Talk
Sun Nov 15
1:00pm–1:05pm
Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5)
Introduction (CE5-1)
New approach methods
Talk
Sun Nov 15
1:05pm–1:30pm
Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5)
FDA's 2025 Roadmap to Reduce Animal Testing: Leveraging NAMs to Address Preclinical Safety (CE5-2)
New approach methods · Regulatory
Talk
Sun Nov 15
2:10pm–2:30pm
Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6)
Regulatory Considerations for Risk Assessment of Immunotherapies (CE6-4)
Immunotoxicology · Regulatory
Talk
Sun Nov 15
3:30pm–4:00pm
Part of Navigating Genetic Toxicology through Drug Development: Interface of Practice, Strategy, and Regulatory Principles (CE7)
Making Decisions on Positive Genotoxicity Results: FDA Guidance on Follow-Up Testing Strategies for Ames-Positive Findings in Drug Development (CE7-5)
Genetic toxicology · Regulatory
Talk
Mon Nov 16
2:55pm–3:15pm
Part of Safety and Regulatory Roadmap for Immune Engagers: Strategies to Translate Novel Modalities (S05)
Safety Assessment of Immune Engagers for Autoimmune Disease: An FDA Perspective (S05-4)
Biologics and new modalities · Regulatory
Talk
Tue Nov 17
11:15am–11:45am
Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09)
Strategic Approaches for a Successful Regulatory submission (S09-6)
Regulatory
Session
Tue Nov 17
2:00pm–5:00pm
Talk
Tue Nov 17
2:00pm–2:15pm
Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10)
Targeted Secondary Pharmacology Panels: Advantages and Applications (S10-1)
Safety pharmacology
Talk
Tue Nov 17
2:20pm–2:50pm
Part of From Policy to Practice: Progress on the FDA’s 2025 Roadmap to Reduce Animal Use in Antibody Platform Development (S12)
The FDA Roadmap and Adoption of NAMs for Regulatory Decision Making (S12-3)
New approach methods · Regulatory
Talk
Tue Nov 17
3:45pm–4:15pm
Part of Safety Assessment of Extractables and Leachables under the New ICH Q3E Guideline (S11)
Safety Assessment Principles for Extractable/Leachables from an FDA Perspective (S11-4)
Chemical risk assessment · Regulatory
Talk
Tue Nov 17
4:15pm–4:45pm
Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10)
A Regulatory Perspective on Secondary Pharmacology and Off-Target Assessments for Pharmaceutical Products (S10-5)
Safety pharmacology · Regulatory
Talk
Wed Nov 18
10:45am–11:15am
Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15)
Assessing Clonal Expansion of Cancer Driver Mutants as an Early Cancer Biomarker (S15-4)
Genetic toxicology
Talk
Wed Nov 18
11:25am–11:45am
Part of Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14)
Regulatory Perspective: Guidance, Expectations, and Safety Pharmacology Assessment (S14-6)
Neurotoxicology · Regulatory
Talk
Wed Nov 18
2:00pm–2:05pm
Part of Hot Topics (S18)
Introduction (S18-1)
with AbbVie
Talk
Wed Nov 18
4:15pm–4:45pm
Part of Hot Topics (S18)
FDA Forensic Investigations of Product Adulteration (S18-6)
Chemical risk assessment
Labcorp
Burlington, NC
Contract research organizations (CROs)
Laboratory services company whose drug development arm runs nonclinical toxicology, pathology and safety studies for drug and chemical developers.
Booth
Exhibiting at Booth 310
Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm
Session
Sun Nov 15
1:00pm–4:30pm
Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5)
New approach methods · with U.S. Food and Drug Administration
  1. 1:00pmIntroduction (CE5-1)U.S. Food and Drug Administration
  2. 1:05pmFDA's 2025 Roadmap to Reduce Animal Testing: Leveraging NAMs to Address Preclinical Safety (CE5-2)U.S. Food and Drug Administration
  3. 1:30pmNew Approach Methodologies (NAMs): Role of Nonclinical Scientists (CE5-3)Gilead Sciences
  4. 2:00pmComplex Human-Derived Models as New Approach Methodologies (NAMs) for Drug Discovery and Development (CE5-4)Sanofi
  5. 3:00pmNew Approach Methodologies in Practice: Creating Virtual Control Groups for Nonclinical Studies (CE5-5)Labcorp
  6. 3:30pmNAMs Adoption in a Global Drug Development Laboratory (CE5-6)Labcorp
Talk
Sun Nov 15
3:00pm–3:30pm
Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5)
New Approach Methodologies in Practice: Creating Virtual Control Groups for Nonclinical Studies (CE5-5)
Study data · New approach methods
Talk
Sun Nov 15
3:30pm–4:00pm
Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5)
NAMs Adoption in a Global Drug Development Laboratory (CE5-6)
New approach methods
Session
Mon Nov 16
9:00am–12:00pm
Beyond the Vessel Wall: Translational Insights into Vascular Inflammation (S03)
Pathology · Translational safety · with Korsana Biosciences
  1. 9:00amIntroduction to Vascular Inflammation (S03-1)Korsana Biosciences
  2. 9:15amDrug Induced Vascular Injury (DIVI) Related to Biologic Therapies: Mechanisms and Sensitivity (S03-2)International Academy of Toxicologic Pathology
  3. 9:45amA Regulatory Perspective (S03-3)ToxStrategies
  4. 10:45amBiomarkers of Vascular Injury (S03-4)Merck
  5. 11:15amInnovative Tools and Future Directions (S03-5)Kymera Therapeutics
Poster
Mon Nov 16
5:00pm–6:30pm
Applying a Virtual Control Group Retrospectively to a 26-Week Subcutaneous Repeat Dose Toxicity Study in the Cynomolgus Monkey (P508)
Nelson Exhibit Ballroom · Poster P508
Study data
Poster
Mon Nov 16
5:00pm–6:30pm
Assessment of a Functional Observational Battery in Minipigs across Multiple Research Sites (P117)
Nelson Exhibit Ballroom · Poster P117
Safety pharmacology · Animal models
Poster
Mon Nov 16
5:00pm–6:30pm
Development of an Integration Site Analysis Assay in AAV2 and AAV9 Administered Murine Models (P301)
Nelson Exhibit Ballroom · Poster P301
Biologics and new modalities · Genetic toxicology
Poster
Mon Nov 16
5:00pm–6:30pm
Enabling Flexible yet Comparable Cell Counting Strategies in Cell and Gene Product Development: A Comparative Evaluation of Automated Platforms (P206)
Nelson Exhibit Ballroom · Poster P206
Biologics and new modalities · Bioanalysis and biomarkers
Poster
Mon Nov 16
5:00pm–6:30pm
Evaluation of Wild Type and Humanized IgG1/4 Göttingen Minipigs for Subchronic Toxicology Assessment of Biotherapeutics (P127)
Nelson Exhibit Ballroom · Poster P127
Animal models · Biologics and new modalities
Poster
Mon Nov 16
5:00pm–6:30pm
Feasibility of a Paddling Pool Test (PPT) as an Alternative Assessment to the Morris Water Maze (MWM) in Mice (P517)
Nelson Exhibit Ballroom · Poster P517
Neurotoxicology
Poster
Mon Nov 16
5:00pm–6:30pm
MRI-Guided Targeted Delivery of AAV9 to the Putamen of Nonhuman Primates and Göttingen Minipigs: A Translational Framework for CNS Gene and Cell Therapies (P302)
Nelson Exhibit Ballroom · Poster P302
Biologics and new modalities · Neurotoxicology
Poster
Mon Nov 16
5:00pm–6:30pm
Nonhuman Primate Species Considerations for Preclinical Gene Therapy Studies (P132)
Nelson Exhibit Ballroom · Poster P132
Animal models · Biologics and new modalities
Poster
Mon Nov 16
5:00pm–6:30pm
Pulmonary Embolism of Marrow Tissue Secondary to Bone Marrow Aspiration for Immunophenotyping in Cynomolgus Monkeys (P136)
Nelson Exhibit Ballroom · Poster P136
Pathology · Animal models
Poster
Mon Nov 16
5:00pm–6:30pm
Validation of the Cincinnati Water Maze for Egocentric Learning and Memory in Developmental Neurotoxicity Studies (P530)
Nelson Exhibit Ballroom · Poster P530
Neurotoxicology · DART
Talk
Tue Nov 17
8:00am–8:55am
Beyond the Roadmaps: Applying Human-Relevant NAMs to Weight-of-Evidence Assessments
Grand Oaks Ballroom Q
New approach methods · Regulatory
Johnson & Johnson
New Brunswick, NJ
Pharmaceutical companies
Healthcare company whose Innovative Medicine arm, formerly Janssen, discovers, develops and markets prescription medicines.
Talk
Sun Nov 15
8:00am–8:05am
Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4)
Introduction (CE4-1)
Regulatory
Session
Sun Nov 15
8:00am–11:30am
Working with Global Regulators for Streamlined Nonclinical Development (CE4)
Regulatory · with MEC Regulatory & Toxicology Consulting
  1. 8:00amIntroduction (CE4-1)Johnson & Johnson
  2. 8:05amTop Tips for Successful Nonclinical Regulatory Interaction (CE4-2)Charles River
  3. 8:30amIdeal Interaction During Drug Development: FDA Regulator's Perspective (CE4-3)U.S. Food and Drug Administration
  4. 9:00amIdeal Interaction During Drug Development: European Regulator's Perspective (CE4-4)Medicines Evaluation Board
  5. 10:00amSponsor Strategies for Successful Regulatory Agency Interactions (CE4-5)Lilly
  6. 10:30amInteractive Workshop: Practical Case Studies to Model Successful Regulatory Agency Interactions (CE4-6)MEC Regulatory & Toxicology Consulting
Talk
Sun Nov 15
9:00am–9:30am
Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3)
Conducting an EFD Study: The Essentials of Getting it Right (CE3-4)
DART
Talk
Sun Nov 15
3:00pm–3:20pm
Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6)
Effectively Evaluating, Understanding, and Communicating the Risky Behavior of Immunotherapies: The Complex and Diverse Role of a Project (Program) Toxicologist (CE6-5)
Immunotoxicology
Talk
Mon Nov 16
2:00pm–2:05pm
Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06)
Introduction (S06-1)
Translational safety
Session
Mon Nov 16
2:00pm–5:00pm
Poster
Mon Nov 16
5:00pm–6:30pm
Validation of Organ-Specific Risk Estimates Derived from a Gene-Based Machine Learning Algorithm (P447)
Nelson Exhibit Ballroom · Poster P447
In silico and AI
Talk
Tue Nov 17
3:45pm–4:15pm
Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10)
Evolving Selectivity Assessment of Biologic Products with Cell-Based Protein Arrays and Derisking Strategies (S10-4)
Biologics and new modalities · Safety pharmacology
Talk
Wed Nov 18
2:25pm–2:45pm
Part of Invisible Ingredients, Critical Functions: The Risk Narrative around Excipients and PFAS (S17)
Risk Communication and Perception of Forever Chemicals and the Consequences for Pharma (S17-2)
Chemical risk assessment

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from companies at ACT 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

When and where is ACT 2026?

47th ACT Annual Meeting runs November 15–18, 2026, at the JW Marriott San Antonio Hill Country Resort & Spa in San Antonio, TX.

What are the ACT 2026 exhibit hall hours?

The exhibit hall is open Mon, Nov 16, 9:30am–6:30pm; Tue, Nov 17, 8:00am–4:30pm.

Where is the ACT 2026 program?

This guide lists every organization on the ACT 2026 program with its sessions; the full program is on the official website.

How do I register for ACT 2026?

Fees and registration are on the organizer's registration page.

What is ACT 2026?

The American College of Toxicology’s 47th Annual Meeting, held November 15–18, 2026 at the JW Marriott San Antonio Hill Country Resort & Spa in San Antonio, Texas. About 1,400 toxicologists attend, most of them in nonclinical safety at pharma and biotech companies, contract research organizations and consultancies, with regulators and academics alongside. The program runs continuing-education courses, symposia, plenary lectures, exhibitor-hosted programs and a poster session, around an exhibit floor ACT calls the ACT Expo.

What is in this guide?

Every organization we can place at ACT 2026: the 89 exhibitors at the ACT Expo with their booth numbers, the 44 organizations on ACT’s supporter list with their level, and the employers of the 272 speakers, chairs and poster presenters on the public program (330 program rows, including 134 posters and the exhibitor-hosted programs) — 231 organizations in one list. People appear as job titles, never by name, and a poster counts only its presenting author, not its co-authors.

Where does this list come from?

Three public pages from the organizer: the meeting’s program and speaker list, the ACT Expo floor plan with each exhibitor’s own profile, and the Annual Meeting supporter list (as of October 6, 2026). Short descriptions are condensed from each exhibitor’s profile or its own website, or state what is well established about the organization. Nothing here requires a login.

How are organizations typed?

By what each organization is or sells to a nonclinical safety team: drug developers (pharma and biotech), contract research organizations and specialist testing labs, consultancies, model and reagent suppliers, instrument and software companies, and universities, agencies and non-profits. The topic tags — regulatory strategy, new approach methods, developmental and reproductive toxicology, pathology, genetic toxicology and more — come from the sessions an organization takes part in and, for exhibitors and supporters, from its own profile and website, at most three each.

How current is it?

Pulled from the meeting’s public program, floor plan and supporter list on October 8, 2026, about five weeks before the meeting. ACT Expo hours are from the schedule. Exhibitors and supporters keep signing up until the meeting, so the lists will grow.

Why are there no names?

This guide is about which organizations are in the room, not which people. It never publishes a person’s name.

Browse ACT 2026 by

Exhibit hall

Organizations with their own page

159 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction